Safety and efficacy for the treatment of C1 and C2 patients with a new method hemodynamic hybrid Nd YAG 1064 LASER and cryosclerotherapy.

OBJECTIVE

To evaluate the safety and efficacy of hemodynamic hybrid LASER cryosclerotherapy for the treatment of chronic venous disease in patients with telangiectasias, reticular veins, and varicose veins.

METHODS

This retrospective cohort included patients classified as C1 and C2 low treated between February 2022 and November 2024. A total of 41 women were included. All patients underwent clinical evaluation, Doppler ultrasound venous mapping for evidence of deep and superficial reflux and standardized pretreatment and post-treatment photography. Exclusion criteria included previous saphenous treatment, thromboembolic events, and Fitzpatrick skin type VI. We used YAG Laser and cooled 67% to 75% dextrose injection.

RESULTS

A total of 71 treatment sessions were performed. Lesion clearance was categorized as insufficient (<50%), moderate (50%-69%), or complete (70%-100%) based on photographic comparison by the treating physician and patient consensus. Complete clearance was achieved in 83% of patients (34/41). Postinflammatory hyperpigmentation was the most common complication, with no cases of skin necrosis. Two minor thrombotic events were observed. No allergic reactions were reported.

CONCLUSIONS

Hemodynamic hybrid LASER cryosclerotherapy appears to be a safe and effective office-based treatment for C1 and C2 low patients, potentially reducing the need for invasive saphenous vein procedures in early-stage chronic venous disease.